Martin Shkreli and Turing Pharmaceuticals are not the only instance where a previously inexpensive generic drug increased in price by more than 400%, said John Bennett, MD, FACC, FACP, president and CEO of CDPHP.
Martin Shkreli and Turing Pharmaceuticals are not the only instance where a previously inexpensive generic drug increased in price by more than 400%, said John Bennett, MD, FACC, FACP, president and CEO of CDPHP.
Transcript (modified)
Rising drug costs have become a bigger focus in the last year, but was this a growing issue that was just ignored until now?
So I think that, for a number of years, particularly through the Great Recession, we had pharmaceutical price trends that were not that excessive. Now a lot of that was really because we moved to a lot of generic drugs and that kind of window has disappeared.
So most companies now have 85%-90% generic prescribing and what we’re seeing, coupled with the explosion of specialty drugs, what we’re seeing is that even though drugs are prescribed generically, we’re seeing that there are many classes which have only 2, maybe 3, generic drug makers, and they are uniformly increasing the prices.
We’re suddenly seeing this huge increase not only in specialty and brand-name drugs, but in generic drugs. People are suddenly acquiring these orphan drugs which were very cheap or even some regular non-orphan drugs—drugs that are used by a wide segment of the population which previously were very cheap—they are acquiring those companies cheaply and just jacking up the price.
So people have to understand for instance that, you know, everyone is familiar with Martin Shkreli who jacked up the price. We could name a hundred instances where previously very inexpensive generic drugs have gone up 400%-500% so that is not a unique circumstance. I think we’re seeing this now and that is what has kind of blossomed.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More